JP Morgan is optimistic about the potential of the CRISPR gene editing pipeline and has initiated coverage with an "overweight" rating and a target price of $70 USD.

J.P. Morgan has upgraded CRISPR Therapeutics (CRSP.US) for the first time to a "neutral" rating, emphasizing the company's unique advantage in the field of gene editing due to its pipeline potential. Analyst Brian Cheng pointed out in the report that as the company's investment portfolio approaches several key development milestones, CRISPR Therapeutics is worth investors' attention again, with a target price set at $70. As a Swiss biotech company collaborating with Vertex Pharmaceuticals Incorporated (VRTX.US) to sell the in vivo gene editing therapy Casgevy, CRISPR is providing the company with a faster path to market entry through its own immune CAR-T candidate drugs (such as CTX112). Brian Cheng specifically mentioned that against the backdrop of the pharmaceutical industry's high focus on cardiovascular targets, the company's in vivo technologies based on ANGPTL3 and Lp(a) candidate drugs provide an attractive opportunity for the company's next growth curve. In the pharmaceutical industry's high focus on cardiovascular targets, these in vivo technologies provide an attractive opportunity for the company's next growth curve. J.P. Morgan further elaborated in the report: "We believe that CRISPR has developed the right strategy and has sufficient resources to mitigate some of the challenges faced by some gene editing peers by striking a balance between its own immune cell therapies and in vivo cardiovascular track."